COMP <GO>
AQST vs ABBV // GROSS PROFIT MARGIN
Aquestive Therapeutics Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: AQST 0
— ABBV 11
▲ GROSS PROFIT MARGIN LEADER: ABBV
LAST: $4.04 (-4.49%) • MKT CAP: $507.1M
gross-margins
58.30%
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
gross-margins
70.20%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AQST VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AQST | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 58.30% | 70.20% | -11.90 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 29.00% | -64.00 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -10.45% | 3.47% | -13.92 | ABBV | /fcf-yield <GO> |
| Operating Margin | -60.00% | 24.60% | -84.60 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 6.90% | -66.90 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | -22.60% | 8.60% | -31.20 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 5.33 | -5.13 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 7/9 | -4.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 37.5 | 65.1 | -27.60 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 113.1x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $507.1M | $513.86B | -$513.35B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AQST REV | ABBV REV | AQST GROSS % | ABBV GROSS % | AQST FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $44.5M | $61.16B | 58.3% | 70.2% | -$53.0M | $17.82B |
| FY 2024 | $57.6M | $56.33B | 69.0% | 70.0% | -$35.9M | $17.83B |
| FY 2023 | $50.6M | $54.32B | — | — | -$6.4M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AQST // BETA —
ABBV // BETA 1.15